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Background: Neisseria meningitidis serogroup C has emerged as a cause of epidemic disease in Hefei. The
establishment of serogroup C as the predominant cause of endemic disease has not been described.
Methods: We conducted national laboratory-based surveillance for invasive meningococcal disease during
2000–2010. Isolates were characterized by pulsed-field gel electrophoresis and multilocus sequence typing.
Results: A total of 845 cases of invasive meningococcal disease were reported. The incidence increased from
1.25 cases per 100,000 population in 2000 to 3.14 cases per 100,000 in 2003 (p < 0.001), and peaked at 8.43 cases
per 100,000 in 2005. The increase was mainly the result of an increase in the incidence of serogroup C disease.
Serogroup C disease increased from 2/23 (9%) meningococcal cases and 0.11 cases per 100,000 in 2000 to 33/58
(57%) cases and 1.76 cases per 100,000 in 2003 (p < 0.01). Patients infected with serogroup C had serious
complications more frequently than those infected with other serogroups. Specifically, 161/493 (32.7%) cases
infected with serogroup C had at least one complication. The case-fatality rate of serogroup C meningitis was
11.4%, significantly higher than for serogroup A meningitis (5.3%, p = 0.021). Among patients with meningococcal
disease, factors associated with death in univariate analysis were age of 15–24 years, infection with serogroup C,
and meningococcemia.
Conclusions: The incidence of meningococcal disease has substantially increased and serogroup C has become
endemic in Hefei. The serogroup C strain has caused more severe disease than the previously predominant
serogroup A strain.
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Meningococcal disease is an important cause of menin-
gitis and sepsis in children and young adults in China
and worldwide. In China, this disease previously oc-
curred in a cyclical pattern at intervals of 8–10 years [1].
Nationwide epidemics occurred in 1959, 1967, 1977, and
1984 [2,3]. Since a national immunisation campaign with
meningococcal A polysaccharide vaccine was initiated in
1982, no countrywide epidemic has occurred, and mor-
bidity rates of meningococcal disease in China have
remained relatively stable at 0.2–1 cases per 100,000* Correspondence: jiabinli948@163.com
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reproduction in any medium, provided the orduring the past two decades [3-5]. During this time, ser-
ogroup A meningococci was most common serogroup
to cause disease and was responsible for more than 95%
of cases, whereas serogroups B cause only sporadic cases
and serogroup C was even rarer [4,5]. However, since
2003 the number of meningococcal meningitis cases at-
tributable to serogroup C has increased substantially in
China [6]. The sudden increase in the number of cases
due to serogroup C meningococci first occurred in Chi-
na’s Anhui Province during 2003–2004. Hefei, the capital
of Anhui Province—a region situated in the middle
China with a population of 1.85 million in 2006—had
one of the first Chinese outbreaks of meningococcal dis-
ease caused by serogroup C [6]. The incidence of menin-
gococcal disease due to serogroup C increased rapidly,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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new epidemic serogroup in Hefei and other areas of
Anhui Province [7]. To control this disease, mass vaccin-
ation using polysaccharide vaccine for serogroup A plus
C in students and children younger than 6 years was un-
dertaken starting in 2004 in Anhui Province [7] Chemo-
prophylaxis was given to close contacts of patients, and
a nationwide surveillance programme was implemented
[7]. No epidemics of meningococcal disease caused by
serogroup C occurred in China before 2002, and few
reports on its epidemiological characteristics in China
have been published [5]. In this article, we report the
replacement of serogroup A disease by serogroup C in
Hefei, China. This led to an increased incidence of dis-
ease among young infants and higher case fatality rates
in the general population.
Methods
Case reporting and laboratory procedures
The protocol of the study adhered to the tenets of the
Declaration of Helsinki and was approved by the ethics
committee of Anhui Medical University. In the National
Notifiable Disease Surveillance System in Hefei, patients
with sudden onset of fever, headache, nausea, vomiting,
stiff neck, petechial rash, accompanied by delirium,
coma or shock, or Gram negative diplococci found in a
smear of cerebrospinal fluid (CSF) by Gram stain should
be reported within six hours to the Center for Disease
Control (CDC), Hefei as suspected cases of invasive
meningococcal disease. In addition to routine examin-
ation and culture in each hospital, blood and/or CSF
from the suspected N. meningitidis patient was sent at
room temperature to the bacteriology laboratory of
Hefei CDC as soon as possible for bacterial culture and
serogroup classification. Within 12 hours of the sus-
pected case being reported, staff at the local Health Bur-
eau conducted a case investigation to understand the
detailed travel history and identify every close contact
during the two weeks before disease onset. If N. menin-
gitidis was isolated and the patient had compatible clin-
ical symptoms and signs, the patient was a confirmed
case of invasive meningococcal disease. The identifica-
tion of all isolates were confirmed at Hefei CDC using
conventional biochemical methods [8]. An agglutination
test (Murex Biotech Ltd, Dartford, UK) for standard ser-
ogroup testing was also performed at Hefei CDC. Ser-
ogroups were determined by slide agglutination
with polyclonal antibodies to capsular polysaccharides
A, C, X, Y, Z, and W135 and monoclonal antibodies to
polysaccharide B.
The minimal inhibitory concentrations (MICs) of the
antimicrobial agents were determined for each isolate by
Mueller-Hinton agar (OXOID Company, Cambridge, UK)
macrodilution method described by the CLSI (formerlythe National Committee for Clinical Laboratory Stan-
dards) [9]. The MIC was defined as the lowest concen-
tration of drug that resulted in no visible growth after
18 h of incubation at 35°C in ambient air. Quality con-
trol strains were included with every batch of clinical
isolates to ensure accuracy and comparable performance
of the assays.
Definitions
Cases were defined as those from which N. meningitidis
was isolated from normally sterile specimens (e.g., CSF,
blood, or joint fluid specimens). In addition, in 2004 the
definition for case patients was broadened to include
patients with culture-negative specimens that yielded po-
sitive results by latex agglutination and Gram stain mi-
croscopy or by latex agglutination and polymerase chain
reaction. Bacteria were identified according to standard-
ized procedures [8]. Laboratory-confirmed meningococ-
cal meningitis was defined as growth of N. meningitidis
on CSF cultures (with or without growth on blood cul-
tures). Laboratory-confirmed meningococcemia was de-
fined as growth of N. meningitidis on blood cultures
(without growth on CSF cultures).
Clinical information collection
We reviewed the available medical information of all
cases reported to Hefei CDC from 1 January, 2000 to 30
December, 2010. The captured data included patients'
history, clinical manifestations and complications, la-
boratory results, therapy, and outcome. Patients were
categorized as either meningitis or meningococcemia.
Incidence
We calculated the incidence based on the number of
laboratory-confirmed cases reported each year from 1
January through 31 December divided by midyear popu-
lation estimates for each year, as supplied by Statistics
Hefei. In 2006, the estimated population of Hefei was
1.85 million.
Statistical analysis
Serogroup C disease was compared with serogroup A
disease alone, because serogroup A has specific epi-
demiological features and had previously been predom-
inant in Hefei. The prevalence of other serogroups in
the area did not vary over time and caused minimal dis-
ease. Univariate assessments of characteristics associated
with disease due to serogroup C infection and disease
resulting in death were performed using Fisher’s exact
test or the Mantel-Haenszel test for categorical variables.
Variables available for evaluation as potential risk factors
included age group, sex, and syndrome (laboratory con-
firmed meningitis versus meningococcemia). Multivari-
able logistic regression models were fitted to the data,
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on univariate analysis and dropping non-significant fac-
tors with stepwise backward selection. Independence of
data was assumed, because the vast majority of cases
were considered to be unrelated. The criterion of signifi-
cance was p < 0.05 in a two-tailed test. Statistical ana-




During 2000–2010, a total of 845 cases of meningococ-
cal disease were reported to Hefei CDC. Table 1 shows
the incidence of meningococcal disease over this time
period. Rates of reported disease increased from 1.25
cases per 100,000 in 2000 to 3.14 cases per 100,000 in
2003 (p < 0.01). In 2005, the incidence peaked at 8.43
cases per 100,000. The increase was mainly the result of an
increase in the incidence of serogroup C disease (Figure 1).
The percentage of cases of serogroup C increased
from 2/23 (9%) of cases and 0.11 cases per 100,000
in 2000 to 33/58 (57%) of cases and 1.76 cases per 100,000
in 2003 (p< 0.01). During 2004–2007, the incidence of
serogroup C exceeded 5.50 per 100,000, whereas the in-
cidence of other serogroups remained relatively stable
(p> 0.05). The incidence of serogroup C steadily de-
creased in the later part of the study period, from 3.14
cases per 100,000 in 2008 to 0.92 cases per 100,000 in
2010 (p< 0.01). During the study period, the incidence
of serogroup A disease remained stable and the propor-
tion of serogroup A cases fluctuated markedly by year.
For the period 2000–2002, a total of 59/74 (80%) cases
were due to serogroup A, with the number decreasing
to 22/58 (38%) cases in 2003. During the period 2004–
2007, the percentage of serogroup A was 10%–15%.
Of the meningococcal strains that were isolated during
this study we analyzed 374 for drug resistance. Sixty-four
(17%) meningococcal isolates were not susceptible to
penicillin. The proportion of resistant isolates fluctuatedTable 1 Number and incidence of laboratory-confirmed invas
CDC, by serogroup, 2000–2010
Year of surv
Serogroup 2000 2001 2002 2003 2004 20
A 20(87) 15(68) 24(83) 22(38) 18(14) 21
C 2(9) 1(5) 3(10) 33(57) 103(80) 129
B 1(4) 3(14) 2(7) 1(2) a 4
X a 3(14) a 2(3) 4(3) 2
Y a a a a 3(2) 3
Total 23 22 29 58 128 1
Incidence 1.25 119 1.57 3.14 6.92 8
NOTE. Data are no. (%) of cases, unless otherwise indicated.
NA, not applicable. a,no isolates identified.by year, from 2/17 (11.8%) isolates in 2000 to a peak
of 16/78 (20.5%) isolates in 2005. Penicillin-resistant
isolates of all serogroups were found. Nine of 97 (9.3%)
serogroup A isolates and 51/264 (19.3%) serogroup C
strains (p = 0.023) were not susceptible to penicillin. The
rate of trimeth-sulfa resistant strains was below 25% in
serogroup A cases and above 50% in serogroup C cases.
All 374 isolates were susceptible to ceftriaxone, cefotax-
ime and cefoxitin, and only 10 isolates were resistant to
rifampin.
Age, sex, and seasonal distribution
In children younger than 14 years, thirty-one percent
(245/792) of cases were serogroup C, and serogroup A
primarily occurred in this age group (Figure 2). Ser-
ogroup C and serogroup A demonstrated different dis-
tributions across age groups. The median age of patients
with serogroup C disease was 19 years (interquartile
range, 6 months–78 years), compared with 2 years
(interquartile range, 2 months–31 years) for serogroup
A disease (p < 0.05). A higher proportion of serogroup C
disease occurred in relatively older age groups. The
highest incidence (13.57 cases per 100,000) and highest
proportion (43.0%) for serogroup C were the 15–24-year
age group, compared with the highest incidence (6.16
cases per 100,000) and highest proportion (54.8%) for
serogroup A in the 1–4-year age group (Figure 2). A
total of 443 cases (75.9%) of serogroup C diseases oc-
curred among persons aged 5–24 years, whereas the
number was only 73 cases (35.1%) for serogroup A dis-
eases. The age of serogroup A cases was younger and
186/208 (89.4%) cases of serogroup A disease occurred
in children younger than 14 years, compared with 236/
(40.4%) cases for serogroup C diseases (p < 0.05). The in-
cidence of serogroup C disease increased for all age group.
Of the 792 serogroup C and serogroup A cases, 444
(56.1%) were male and 348 (43.9%) were female. The
distribution showed no significant difference between
the two groups (Mann–Whitney U test: p = 0.33).ive meningococcal cases in Hefei reported to The Hefei
erillance
05 2006 2007 2008 2009 2010 Total
(13) 13(10) 19(15) 17(22) 18(41) 21(49) 208
(83) 112(84) 106(81) 55(71) 23(52) 17(40) 584
(3) 3(2) 5(4) 2(3) a 3(7) 24
(1) 3(2) a 1(1) 2(6) 1(2) 18
(2) 1(1) 1(0.8) 2(3) 1(2) a 11
56 134 131 77 44 43 845





























Serogroup A disease 
Serogroup C disease 
Total disease 
Figure 1 Incidence of laboratory-confirmed invasive meningococcal disease by serogroup in Hefei, China, as reported to the Hefei CDC
for Communicable Diseases.
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http://www.biomedcentral.com/1471-2334/12/205The monthly distribution of patients shows that the
lowest incidence is in the summer months and the high-
est incidence is in the late winter months (data not
shown). There were no statistically significant differences
in seasonal characteristics between cases infected with
serogroup C and serogroup A (data not shown).
Comparison of clinical features between serogroup C and
serogroup A cases
Complete detailed clinical information was available on
84% (493/584) of patients with serogroup C and 85%
(177/208) of patients with serogroup A. The frequency
of presenting symptoms, sign, and laboratory findings of
the patients are shown in Table 2. Patients with ser-





























Figure 2 Annual age-specific incidence of confirmed serogroup C andpurpura (80.3% versus 73.4%; OR: 1.46; 95% CI: 0.98–
2.18), but the difference did not achieve statistical sig-
nificance. When compared with serogroup A disease,
serogroup C disease was more likely to cause meningo-
coccemia (76.9% versus 48.0%; OR: 3.60; 95%CI: 2.51–
5.17; p < 0.001). Patients with serogroup C were more
likely to have a decreased platelet count (26.7% versus
8.5%, p < 0.001). Patients infected with serogroup C were
more frequently involved in serious complications; 161/
493 (32.7%) cases infected with serogroup C had at least
one complication, whereas only 23/177 (13.0%) of ser-
ogroup A cases had complications (p < 0.001). Patients in
serogroup C were significantly more likely than those in
serogroup A to have shock (18.5% versus 7.3%; p <0.001)




A invasive meningococcal disease in Hefei, China, 2000-2010.
Table 2 Clinical manifestations, laboratory data, and
outcome of 670 meningococcal disease patients with









1.8 ± 2.5 1.9 ± 2.4 0.810
Fever 481(97.6) 169(95.5) 0.162
Nausea and/or vomiting 141(28.5) 55(31.2) 0.535
Headache 165(33.4) 52(29.1) 0.319
Petechia and/or purpura 396(80.3) 126(73.4) 0.063
Altered mental status 136(27.6) 49(27.7) 0.980
Disease classification
Meningitis 114(23.1) 92(52.0) <0.001
Meningococcemia 379(76.9) 85(48.0)
With Shock 91(18.5) 13(7.3) <0.001
With pneumonia 12(2.8) 3(1.7) 0.784
With arthritis 9 (1.8) 4(2.3) 0.967
Complications 161 23 <0.001
Shock 91(18.5) 13(7.3) <0.001
DIC 60(12.2) 7(4.0) 0.002
kidney failure 10(2) 3(1.7) 0.783
MOF 4(0.8) 1(0.6) 1.0
WBC count
>10 × 109/L 302(61.3) 99(56.1) 0.019
10~4× 109/L 117(23.7) 35(19.8)
<4 × 109/L 74(15.0) 43(24.3)
Platelet count
>100× 109/L 361(73.2) 162(91.5) <0.001
100~50× 109/L 87(17.6) 11(6.2)
100~50× 109/L 87(17.6) 11(6.2)
CSF data (mean± SD)
Glucose level(mmol/L) 2.07 ± 1.7 1.91 ± 1.8 0.717
CSF glucose / blood
glucose ratio
0.24 ± 0.23 0.21 ± 0.29 0.438
Total protein level(g/L) 3.41 ± 2.9 3.17 ± 2.18 0.106
Lactate level(mmol/L) 10.4 ± 9.2 11.0 ± 8.9 0.113
WBC count(109/L) 5.3 ± 13.8 8.1 ± 13.6 0.895
Sequelae 46/484(9.5) 6/171(3.5) 0.013
Scars 19/484(3.9) 2/171(1.2) 0.132
Amputations 14/484(2.9) 0 0.026
sensorineural hearing loss 5/484(1.0) 3/171(1.8) 0.739
Others 8/484(17) 1/171(0.6) 0.516
Death 55/484(11.4) 9/171(5.3) 0.021
NOTE. Data are no. (%) of patients, unless otherwise indicated.
WBC: white blood cells. DIC: disseminated intravascular coagulation.
MOF: multiple organ failure.
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tiple organ failure, 14 (77.8%) had serogroup C disease.
There was adequate information to objectively assess
sequelae in 655 survivors. About nine percent of ser-
ogroup C cases (46 of 484 cases) and 4% of serogroup A
cases (6 of 171) were affected (p = 0.013). For survivors
of serogroup C disease, skin scars (3.9%) and amputa-
tions (2.9%) were the most frequent problems observed.
Other problems of serogroup C survivors were perman-
ent minor reduction in kidney function (n = 3) perman-
ent knee damage following septic arthritis causing mild
reduction in mobility (n = 2), partial paralysis (n = 1), and
speech problem (n = 1). One survivor of serogroup C
disease developed multiple neural deficits following an
intracerebral hemorrhage.
During the period of study, a total of 64 fatal cases
were reported to Hefei CDC. During 2000–2002, only
four fatal cases were reported and the case-fatality rate
remained relatively low (4/74 cases; 5.4%). However,
case-fatality rates increased to 15.5% (9/58) in 2003 and
peaked at 17.3% (22/127 This increase was mainly due
to increasing deaths caused by serogroup C disease.
Table 3 shows that the case-fatality rate of serogroup C
meningitis was 11.4%, significantly higher than serogroup
A meningitis (5.3%, p = 0.021). Among patients with in-
vasive serogroup C or A disease, factors associated with
death in univariate analysis were age of 15–24 years,
infection with serogroup C, and meningococcemia
(Table 3). In multivariable analysis, age group and
meningococcemia were significantly associated with
death. There was a marginal association between ser-
ogroup C infection and an increased risk of dying
(adjusted OR, 2.73; p= 0.052).
Discussion
Although N. meningitidis serogroup C is a prominent
serogroup in many regions of the world and has occa-
sionally caused epidemics and frequently causes out-
breaks [10], only sporadic cases and no epidemics of
meningococcal disease due to serogroup C occurred in
China before 2002. In this study, we report the emer-
gence of endemic serogroup C meningococcal disease
and epidemiological characteristics in China. The rate of
invasive meningococcal disease in Hefei increased 2.5
times from 2000 to 2003, and the incidence peaked at
8.43 cases per 100,000 in 2005. This increase was mostly
because of the emergence and increase in the incidence
of serogroup C disease.
The reasons for the emergence and increase in ser-
ogroup C disease in Anhui Province and parts of China
(while other potentially epidemic strains have remained
relatively quiescent) are not fully understood. It is well-
known that molecular mechanisms likely play an im-
portant role in the epidemiology of meningococcal
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change its characteristics, such as antigenic structure
and resistance to antibiotics. Many of these changes
occur through horizontal gene transfer, by which the or-
ganism obtains large DNA sequences from other menin-
gococcal strains or other species [11]. Capsular
switching is a genetic mechanism that allows N. menin-
gitidis to change its capsular phenotype, permiting im-
munologic escape [12,13]. N. meningitidis outbreaks can
be started or sustained when this occurs. Capsular
switching appears to have been responsible for an out-
break of serogroup W-135 disease during the 2000
Hajj in Mecca, Saudi Arabia. Subsequent to this out-
break, the epidemic strain spread globally and, in one ex-
ample, caused an epidemic in Burkina Faso [14,15].
Selected isolates of the serogroup C clone from Hefei
and the rest of Anhui Province were found to belong to
ST-4821, a unique clone of serogroup C that does not be-
long to any of the previously reported sequence types
[16]. For this reason, capsular switching may have been a
cause for the emergence of serogroup C in Anhui Prov-
ince. Published data showed that this unique ST-4821
clone was first identified in Anhui Province during
2003–04, and the same ST clones were also identified in
11 other provinces in China during 2004–2005 [7,16,17].Table 3 Univariate and multivariable analyses of risk factors
in Hefei, 2000–2010

















Strain’s susceptibility to penicillin
Susceptible 37/288(12.8)
Non-susceptible 9/52(17.3)
a Two cases of arthritis with positive synovial fluid culture results were excluded.The overall case-fatality rate in Hefei tripled from
2000 to 2003. We report that the rate of case-fatality
with serogroup C was 2.2 times that of serogroup A dur-
ing the period covered. This was of borderline statistical
significance and factors associated with death in univari-
ate analysis were age of 15–24 years, infection with ser-
ogroup C, and meningococcemia. The results of this
study confirm the severity of serogroup C disease
[18,19]. The reason for the high virulence of this particu-
lar strain of N. meningitidis is unknown, but the strain is
associated with a high frequency of meningococcemia
with severe complications, which was of statistical sig-
nificance in multivariable analysis. Meningococcemia
was also independently associated with serogroup C dis-
ease and with increased risk of death. Meningococcemia
has a higher case-fatality rate than meningitis [20].
Few published papers discuss the clinical characteris-
tics of serogroup C meningococcal disease [18-20]. We
reviewed the detailed clinical information and found ser-
ogroup C disease more likely to cause meningococcemia,
decreased platelet counts, and serious complications.
Our findings provide valuable information to understand
the severity of serogroup C disease. Several scoring sys-
tems have been developed for assessing the prognosis
and mortality of meningococcal disease [21-24]. Thefor death in serogroup C and A meningococcal infection
atients (%) Univariate analysis Multivariable analysis
OR (95% CI) P OR (95% CI) p
Reference
Reference
Reference <0.001 Reference <0.001
0.08(0.03-0.13) 0.20 (0.11–0.38)
0.06(0.02-0.1) 0.13 (0.07–0.27)
0.17(0.13-0.2) 0.97 (0.24–3.86) 15-24
0.02(0.01-0.09) 0.13 (0.07–0.27) 25-44
Undefined Undefined >44
Reference 0.003 Reference 0.002
2.92(1.41-6.02) 3.21 (0.89–11.56)
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a good example of a clinical prediction tool for assessing
the mortality of meningococcal disease [21,22]. Most of
those scoring systems are based on easily available clin-
ical and laboratory parameters such as age distribution,
period between onset of disease and admission, absence
of meningitis, presence of widespread skin lesions, hy-
potension, metabolic acidosis, normal C-reactive protein
level, absence of leukocytosis, presence of thrombo-
cytopenia, and hypofibrinogenemia [21-24]. However,
some of the above factors (e.g., C-reactive protein and fi-
brinogen levels) were not routinely checked in our cases.
Of note, the age distribution of patients shifted from
younger to older age categories in the Hefei area during
the study period. From 1989 to 1999, 78% of cases of
meningococcal disease occurred in children younger
than 14 years [4]. However, the proportion of cases in
this age group decreased to 31% from 2000 to 2010,
while the proportion in 15–24 year olds increased from
22% (1989–1999) to 52.6% (2000–2010). The elevated
incidence of meningococcal disease among adolescents
and young adults has also been noted in previous studies
[15,25]. Some reports indicated that the age distribution
was not uniform for all serogroups, and disease caused
by serogroup C was more likely to affect older children
than disease caused by serogroup B [26]. However, an-
other study regarded the shift toward older age as a
characteristic of a meningococcal disease epidemic, and
suggested that the age distribution of the disease would
return to “normal” after the epidemic [27]. Possible
explanations for the change in age group affected in-
clude: N meningitidis of serogroup C was antigenically
new to the entire population; adolescents and young
adults have enhanced risk factors for meningococcal
transmission and invasion, such as crowding, active or
passive smoking, and exposure to oral secretions. Under-
standing the age distribution of meningococcal disease is
necessary to devise control and preventive measures
such as vaccinations for high-risk populations. Because
serogroup C is a vaccine-preventable strain, our findings
stress the importance of further study of the age distri-
bution of this disease. In the early days of an outbreak of
serogroup C meningococcal disease (2003–2004) in
Anhui Province, serogroup C vaccine was only recom-
mended for children younger than two years. In 2005
serogroup C meningococcal conjugate vaccine was
introduced to all those who were younger than 25 years,
especially for those populations such as middle school
students, college freshmen and service personnel. From
September 2003 to July 2007, 627,000 doses of ser-
ogroup A and C vaccine were used in Hefei, providing
an estimated 37–51% coverage of the population aged
2–24 years. After the immunization campaign in Hefei,
the incidence of serogroup C meningococcal diseasedecreased. In addition, serogroup C meningococcal
pharyngeal carriage has likely been reduced, which has
likely led to a reduction in serogroup C meningococcal
disease in the unimmunized population.
Conclusion
The incidence of meningococcal disease substantially
increased in Hefei from 2000 through 2010. This was
mainly the result of an increase in the incidence of ser-
ogroup C disease, and serogroup C has become endemic
in Hefei. Patients infected with serogroup C had greater
disease severity more frequently than those infected with
serogroup A, the previous predominant serogroup.
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